ARG2 - arginase 2 Gene

Species: Homo sapiens

Gene Type: protein coding

Gene ID: 384

About ARG2

Cytogenetic location: 14q24.1 Genomic coordinates (GRCh38): 14:67,619,920-67,651,708 (from NCBI)

This gene has 4 transcripts (splice variants), 212 orthologues and 2 paralogues. Broad expression in thyroid (RPKM 94.3), prostate (RPKM 64.4) and 23 other tissues.

Summary

Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian Arginase exists (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type II isoform encoded by this gene, is located in the mitochondria and expressed in extra-hepatic tissues, especially kidney. The physiologic role of this isoform is poorly understood; it is thought to play a role in nitric oxide and polyamine metabolism. Transcript variants of the type II gene resulting from the use of alternative polyadenylation sites have been described. [provided by RefSeq, Jul 2008]

ARG2 Products (1)

mRNA	Protein	Name
NM_001172.4	NP_001163.1	arginase-2, mitochondrial precursor

Gene Ontology

Molecular Function
Biological Process

Molecular Function GO Annotation	Evidence	References	Source
enables arginase activity	IMP IMP: Inferred from mutant phenotype	16128822	GOA
enables protein binding	IPI IPI: Inferred from physical interaction	32814053	GOA

Biological Process GO Annotation	Evidence	References	Source
involved in negative regulation of tumor necrosis factor production	IMP IMP: Inferred from mutant phenotype	28614294	GOA
involved in positive regulation of cellular senescence	IDA IDA: Inferred from direct assay	22928666	GOA

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

ARG2 Protein Structure

Arginase

0
100
200
300
354 a.a.

Protein Preferred Names	Protein Names
arginase-2, mitochondrial	L-arginine amidinohydrolase

ARG2 Protein-protein interaction Information

Type	Protein Name	Protein ID	Interactor	Interactor Species	Interactor ID	Detection Method	References
Intra	ARG2	P78540	FOXD4L6	Homo sapiens	Q3SYB3	Validated Y2H	32814053
Intra	ARG2	P78540	FOXD4L6	Homo sapiens	Q3SYB3	Y2H Array	32814053
Intra	ARG2	P78540	FOXD4L6	Homo sapiens	Q3SYB3	Y2H Pooling	32814053

Cross: Cross-species interaction Intra: Intraspecies interaction

Recombinant ARG2 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P7603	Arginase-2/ARG2 Protein, Human (His)	P78540 (H24-G330)	≥ 95%, as determined by reducing SDS-PAGE.

ARG2 Antibodies

Cat. No.	Product Name	Application	Reactivity
HY-P810849	Arginase 2 Antibody	WB, IHC-P, ICC/IF	Human, Monkey
HY-P83148	Arginase 2 Antibody (YA2893)	WB, ICC/IF, FC	Human

Related Diseases

Diseases	Alias
Argininemia	Hyperargininemia Arginase Deficiency Arg1 Deficiency Arginase-1 Deficiency Deficiency Of Canavanase Arginase Deficiency Disease ARGIN
Ovarian Wilms' Cancer	Ovarian Wilms' Tumor
Urea Cycle Disorder	Urea Cycle Disorders Urea Cycle Disorders, Inborn Disorder Of Metabolism Of Ornithine, Citrulline, Argininosuccinic Acid, Arginine And Ammonia Disorder Of Urea Cycle Metabolism Urea Cycle Defect Ucd Disorder Of The Urea Cycle Metabolism Disorder Of Urea Cycle Disorders Of Metabolism Of Ornithine, Citrulline, Argininosuccinic Acid, Arginine And Ammonia Ammonia Metabolic Disorder
Impotence	Erectile Dysfunction Sexual Impotence Erectile Dysfunction Adverse Event
Argininosuccinic Aciduria	Argininosuccinate Lyase Deficiency Asl Deficiency Argininosuccinic Acid Lyase Deficiency Argininosuccinase Deficiency Argininosuccinic Acidemia Arginosuccinase Deficiency Asa Deficiency Argininosuccinicaciduria Asauria Deficiency Of Argininosuccinate Lyase Asld Arginino Succinase Deficiency Argininosuccinate Acidemia Inborn Error Of Urea Synthesis, Arginino Succinic Type Urea Cycle Disorder, Arginino Succinase Type Argininosuccinyl-Coa Lyase Deficiency Asa Argininosuccinatelyase Deficiency ARGINSA Aciduria Argininosuccinic Citrullinemia Argininosuccinic Acidaemia Metabolic Disorder Of Arginosuccinic Acid
Asthma	Chronic Obstructive Asthma Asthma, Diminished Response To Antileukotriene Treatment In Bronchial Hyperreactivity Asthma, Susceptibility To Asthma, Bronchial Asthma, Protection Against Asthma, Nocturnal, Susceptibility To Nocturnal Asthma Asthma-Related Traits Asthma-Related Traits, Susceptibility To Asthma, Nocturnal Chronic Obstructive Asthma With Acute Exacerbation Chronic Obstructive Asthma With Status Asthmaticus Exercise Induced Asthma Exercise-Induced Asthma Bronchial Asthma Asthma, Exercise-Induced Idiosyncratic Asthma Unspecified Asthma With Acute Exacerbation Asthma, Unspecified, With Stated Status Asthmaticus Status Asthmaticus Nos Acute Severe Asthma Acute Severe Bronchial Asthma Status Asthma Status Post Asthmaticus
Priapism	Mentulagra Priapism, Familial Idiopathic Familial Idiopathic Priapism Pathologic Erection Painful Erection
Citrullinemia, Classic	Citrullinemia Classic Citrullinemia Argininosuccinate Synthetase Deficiency Ass Deficiency Citrullinemia Type I CTLN1 Citrullinuria Citrullinemia, Type I Argininosuccinic Acid Synthetase Deficiency Ctnl1 Citrullinemia 1 Deficiency Of Citrulline-Aspartate Ligase Cit Argininosuccinate Synthase Deficiency Argininosuccinic Acid Synthase Deficiency Citrullinemia Type 1 Citrullinemia Classical
Penile Disease	Penile Diseases
Inhibited Male Orgasm	Male Orgasmic Disorder Psychosexual Dysfunction With Male Orgasmic Disorder
Spastic Diplegia	Diplegic Infantile Cerebral Palsy Little'S Disease Cerebral Palsy Cerebral Spastic Infantile Paralysis Infantile Diplegic Cerebral Palsy Infantile Spastic Cerebral Palsy Littles Disease Spastic Cerebral Palsy
Visceral Leishmaniasis	Kala-Azar Leishmaniasis, Visceral Infection By Visceral Leishmaniasis Leishmaniasis Visceral Sahib Disease Ponos Burdwan Fever Mard El Bicha Sirkari Disease Indian Visceral Leishmaniasis Dumdum Fever Visceral Leishmaniasis Due To Leishmania Donovani
Hypertension, Essential	Essential Hypertension Hypertension High Blood Pressure Hypertension, Essential, Susceptibility To Hypertensive Disease Primary Hypertension EHT Hypertension, Salt-Sensitive Essential, Susceptibility To Hyperpiesia Idiopathic Hypertension Hypertensive Disorder Hypertension, Essential, Susceptibility To, 3 Hypertension, Essential 3 Hypertension, Essential, Salt-Sensitive Hypertension, Essential, Susceptibility To, 6 Hypertension, Essential 6 Hypertension, Salt-Sensitive Essential Hypertension, Susceptibility To Hypertension, Essential, Susceptibility To, 4 Hypertension, Essential 4 Hypertension, Essential, Susceptibility To, 2 Hypertension, Essential 2 Hypertension, Essential, Susceptibility To, 1 Hypertension, Essential 1 Hypertension, Essential, Susceptibility To, 5 Hypertension, Essential 5 Htn Vascular Hypertensive Disorder Systemic Primary Arterial Hypertension Hbp - [High Blood Pressure] Systemic Arterial Hypertensive Disorder Elevated Blood Pressure Arterial Hypertension Nos Hypertension Nos Benign Hypertension Systemic Arterial Hypertension Systemic Hypertension Artery Htn Benign Htn Vascular Htn Vascular Hypertension Cholesterol Hypertension Cholesterol Htn Idiopathic Htn Malignant Hypertension Malignant Htn Raised Blood Pressure Cardiovascular Hypertension Primary Htn - [Hypertension] High Arterial Tension High Blood Pressure Disorder Ht - [Hypertension] Htn - [Hypertension] Hypertensive Vascular Disease Hypertensive Vascular Degeneration
Myopathy	Muscular Diseases Myopathies

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Approval
Clinical Phase
Pre-clinical Phase

Approval

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-16254	Hydrocortamate hydrochloride	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Phase
HY-112885	nor-NOHA		/	Phase 1

Pre-clinical Phase

Bioactive Molecules (8)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-112885B	nor-NOHA monoacetate		99.99%	Unkown
HY-112885C	nor-NOHA dihydrochloride		99.61%	Unkown
HY-112885A	nor-NOHA acetate		99.52%	Unkown
HY-RS00908	ARG2 Human Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-P4750	Acetyl-(D-Arg2)-GRF (1-29) amide (human)	Antagonist	99.67%	Unkown
HY-P10555	(D-Arg2, Sar 4)-Dermorphin (1-4)	Agonist	/	Unkown
HY-RS17404	Arg2 Mouse Pre-designed siRNA Set A	Pre-designed Set	/	Unkown
HY-RS23859	Arg2 Rat Pre-designed siRNA Set A	Pre-designed Set	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Canis familiaris	ARG2	VGNC	VGNC:38042
Macaca mulatta	ARG2	VGNC	VGNC:70005
Felis catus	ARG2	VGNC	VGNC:68069
Mus musculus	ARG2	MGD	MGI:1330806
Bos taurus	ARG2	VGNC	VGNC:26071
Rattus norvegicus	ARG2	RGD	RGD:2151
Others	ARG2	NCBI